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Article focus
  to determine the level of inter- and intra-
rater agreement in the diagnosis of surgi-
cal site infection in the context of a clinical 
trial.
Key messages
  there is substantial agreement among 
the members of the PARItY CAC 
regarding the presence or absence of sur-
gical site infection.
  Agreement on the level of infection, how-
ever, is more challenging.
  Additional clinical information routinely 
collected by the prospective PARItY trial 
may improve the discriminatory capacity 
of the CAC in the parent study for the 
diagnosis of infection.
The inter-rater reliability of the diagnosis 
of surgical site infection in the context of 
a clinical trial
Objectives
The diagnosis of surgical site infection following endoprosthetic reconstruction for bone 
tumours is frequently a subjective diagnosis. Large clinical trials use blinded central Adju-
dication committees (cAcs) to minimise the variability and bias associated with assessing 
a clinical outcome. The aim of this study was to determine the level of inter-rater and intra-
rater agreement in the diagnosis of surgical site infection in the context of a clinical trial.
Materials and Methods
The prophylactic Antibiotic Regimens in Tumour surgery (pARITY) trial cAc adjudicated 29 
non-pARITY cases of lower extremity endoprosthetic reconstruction. The cAc members clas-
sified each case according to the centers for Disease control (cDc) criteria for surgical site 
infection (superficial, deep, or organ space). combinatorial analysis was used to calculate 
the smallest cAc panel size required to maximise agreement. A final meeting was held to 
establish a consensus.
Results
Full or near consensus was reached in 20 of the 29 cases. The Fleiss kappa value was cal-
culated as 0.44 (95% confidence interval (cI) 0.35 to 0.53), or moderate agreement. The 
greatest statistical agreement was observed in the outcome of no infection, 0.61 (95% cI 
0.49 to 0.72, substantial agreement). panelists reached a full consensus in 12 of 29 cases and 
near consensus in five of 29 cases when cDc criteria were used (superficial, deep or organ 
space). A stable maximum Fleiss kappa of 0.46 (95% cI 0.50 to 0.35) at cAc sizes greater 
than three members was obtained.
Conclusions
There is substantial agreement among the members of the pARITY cAc regarding the pres-
ence or absence of surgical site infection. Agreement on the level of infection, however, 
is more challenging. Additional clinical information routinely collected by the prospective 
pARITY trial may improve the discriminatory capacity of the cAc in the parent study for the 
diagnosis of infection.
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Strengths and limitations
  there is no universal standard for a kappa value that 
describes acceptable or unacceptable levels of agreement
  the information recorded for the clinical vignettes 
may have suffered from multiple collection and 
reporting biases inherent in the construction of a 
patient's chart.
  this study is an important step towards calibration for 
the PARItY trial CAC.
Introduction
In large clinical trials, Central Adjudication Committees 
(CACs) are often used to minimise the variability in out-
comes assessment associated with having multiple investi-
gators at multiple sites.1,2 CACs typically consist of three or 
more physicians who are experts in their field, and are 
experienced in clinical research.3,4 CACs operate according 
to pre-defined Adjudication Charters, and they assess out-
come events according to predefined criteria. use of CACs 
in large clinical trials significantly increases data quality 
and reduces research inaccuracy by minimising between-
site variability and biased outcome assessment.1,2,5
the Prophylactic Antibiotic Regimens in tumour 
surgery (PARItY) trial is a multicentre, blinded, ran-
domised controlled trial, using a parallel two-arm design 
to investigate whether long-duration post-operative anti-
biotic regimens (five days) will decrease the rate of deep 
surgical site infection among patients being surgically 
treated for a lower extremity bone tumour in comparison 
with short-duration post-operative antibiotics (24 hours).6
the primary outcome for the PARItY trial is the rate of 
surgical site infections in each arm within one year of sur-
gery, an end point that relies heavily on subjective clinical 
judgement.7 Experts agree that a universal benchmark test 
for diagnosing deep post-operative infection does not cur-
rently exist.8 Multiple reports have investigated the role of 
serologic, microbiological, and diagnostic imaging tests, 
but the treating surgeon’s interpretation of these findings, 
in combination with history and physical examination, is 
essential.7 In prior studies of surgical site infection for 
endoprosthetic reconstruction for bone tumours, diagnos-
tic criteria have been variably defined.9 our systematic 
review identified that only two studies10,11 reported using 
the Centers for Disease Control (CDC) criteria for a deep 
post-operative wound infection, and few reported on 
commonly used serologic and laboratory parameters.10 
given the variability in defining the primary outcome, it is 
essential to demonstrate that the methods to be used by 
the PARItY CAC will allow the CAC to agree reliably on the 
presence or absence of surgical site infection.1,5
Study questions
-  What is the level of inter-rater and intra-rater agree-
ment of the PARItY CAC in the diagnosis of surgical 
site infection?
-  Does the use of the CDC criteria for surgical site 
infection increase or decrease the level of agreement 
of the CAC?
- What is the optimal size of the PARItY CAC?
-  Do formal consensus meetings change the results 
significantly from the majority opinion of independ-
ent reviewers?
Materials and Methods
Study design and setting. this study assessed the inter- 
and intra-rater agreement of determining post-operative 
wound infections following wide surgical excision and 
endoprosthetic reconstruction for lower extremity pri-
mary bone tumours.
Participants. the CAC for the PARItY trial is a five-mem-
ber panel of orthopaedic surgeons and an infectious dis-
ease specialist. the PARItY CAC members were asked to 
adjudicate 29 non-PARItY cases of lower extremity endo-
prosthetic reconstruction. Cases were identified without 
randomisation from the databases of two separate sar-
coma centres. these cases were selected by the PARItY 
group by consensus to represent a range of potential 
clinical situations that were likely to be encountered in 
the PARItY trial. For all cases, a comprehensive search for 
all contemporaneously recorded clinical data, including 
laboratory results, clinical notes, and radiographic stud-
ies, was undertaken. All clinical data at the time of diagno-
sis of infection, if applicable, were exhaustively collected. 
short clinical vignettes, including all relevant recorded 
information from each patient’s electronic and physical 
records, were presented in a survey format (example 
case in supplementary material). Ethical approval for col-
lection of these data was granted by the research ethics 
boards of the involved hospitals.
Description of experiment. All reviewers were first asked 
to review the CDC criteria for surgical site infection12 
and to familiarise themselves with this classification sys-
tem (see supplementary material). In order to determine 
inter-rater reliability, all members of the CAC were asked 
independently to determine the presence or absence of 
infection for each case according to the CDC criteria for 
surgical site infection. Each reviewer was asked to spec-
ify whether or not the case was familiar to him or her. 
Reviewers were also able to select ‘unable to assess’ as an 
option if they felt that there was inadequate information 
contained within the clinical vignette to reach a conclu-
sion as to the presence or absence of infection. However, 
reviewers were encouraged to reach a decision if at all 
possible. Intra-rater reliability was determined by repeat-
ing the survey using identical cases three months after 
initial responses were collected. A consensus meeting 
was held and all cases were discussed between all com-
mittee members until a consensus opinion on each case 
was determined. No communication about the cases or 
classification system occurred between reviewers before 
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the consensus meeting. All discussions were continued 
until a consensus position was reached for all cases. At 
the conclusion of the consensus meeting, the opinions of 
the reviewers regarding their experiences with the appli-
cation of the classification system were collected.
Variables, outcome measures, data sources and bias. the 
results of each round of the survey were collected for 
each reviewer, who was asked to identify if the case was 
recognisable to them. After the first round of the survey, 
inter-rater reliability was calculated. In order to reflect the 
primary outcome measure of the PARItY study, the CDC 
categories of 'superficial incisional surgical site infection', 
'deep incisional surgical site infection', and 'organ/space 
surgical site infection' were aggregated into a single cat-
egory of ‘infection’ and compared with the single category 
of 'no infection'. this binary outcome measure was ana-
lysed independently for inter-rater reliability. ‘unable to 
assess’ was an available category for the reviewers to select 
throughout the study and was incorporated into all statisti-
cal analyses. the first round of survey data was also used to 
simulate CAC groups of varying sizes using combinatorial 
analysis. After the second round of the survey, the paired 
responses of each reviewer were analysed for intra-rater 
reliability. After concluding both rounds of the survey, a 
final CAC consensus meeting was held. Reviewers were 
asked to review the clinical information presented in each 
vignette and come to a consensus opinion for both the 
CDC classification of surgical site infection and the binary 
outcome measure. All reviewers were blinded to the results 
of the initial round of the survey until the final CAC meet-
ing. these results were compared with the majority opin-
ion for each case established in the first round of the survey.
All cases from the first round of the survey that did not 
reach strict consensus (all five members in agreement) on 
both the CDC level of infection and the aggregated binary 
outcome measure were referred to the CAC consensus 
meeting for discussion. Discussions were timed and min-
utes taken to observe qualitatively patterns that may have 
led to the lack of agreement.
Statistical analysis. the primary outcome to be investi-
gated in each round of the survey was categorical, there-
fore agreement was calculated using the Fleiss kappa 
statistic.13 landis and Koch14 proposed the following 
standards for strength of agreement for the kappa coef-
ficient: poor (0.01 to 0.20); slight (0.21 to 0.40); fair 
(0.41 to 0.60); moderate (0.61 to 0.80); and substantial 
(0.81 to 1.00). the calculation was repeated excluding 
responses in cases where the reviewer identified that the 
case was known to them.
An a priori power calculation estimated that 29 cases 
will provide 80% power to exclude a kappa of 0.40 or 
lower, if the true underlying kappa is 0.90 or higher, at an 
alpha of 0.05. With five reviewers evaluating 29 cases, 
confidence intervals (CI) around kappa were estimated at 
+/− 0.115.15,16
Intra-rater agreement was calculated using the Cohen 
kappa statistic.17 Combinatorial analysis of all possible com-
binations of CACs of sizes ranging from two to five mem-
bers was analysed using the Fleiss kappa statistic (or Cohen’s 
kappa statistic in the case of two member panels).
All statistical analyses were in Microsoft Excel 
(Microsoft, Redmond, Washington) using the Real 
statistics Resource Pack data analysis add-in.18
Results
What is the level of inter- and intra-rater agreement of 
the PARITy CAC in diagnosing surgical site infection? All 
five panelists (full consensus) or four of five panelists 
(near consensus) agreed on the presence or absence of 
surgical site infection in 20 of the 29 cases. the Fleiss 
kappa value was calculated as 0.44 (95% CI 0.35 to 
0.53), which is consistent with moderate agreement. 
Absolute agreement between reviewers was 80% for 
presence or absence of infection, and 75% using the 
CDC criteria (see supplementary material). Following 
the second round of adjudication, intra-rater agreement 
was substantial (0.67, 95% CI 0.87 to 0.47) for presence 
or absence of infection, and moderate for CDC criteria 
(0.57, 95% CI 0.75 to 0.39) (table I).
Does use of the CDC criteria for surgical site infec-
tion increase or decrease the level of agreement of the 
CAC? When asked to classify each clinical vignette accord-
ing to the CDC criteria for deep or organ/space surgical 
site infection, panelists reached a full consensus in 12 out 
of 29 cases and near consensus in five of 29 cases. this 
corresponded to a kappa of 0.35 (95% CI 0.28 to 0.42), 
which is fair. When all possible responses were exam-
ined, the greatest statistical agreement was observed in 
the outcomes of no infection, 0.61 (95% CI 0.49 to 0.72), 
consistent with substantial agreement, and any infection, 
0.58 (95% CI 0.47 to 0.70), indicating moderate agree-
ment (table I). When responses from CAC members 
who identified that they were familiar with the case were 
excluded, the level of agreement identified by this analy-
sis did not change significantly from the data above with 
a kappa of 0.29 (95% CI 0.22 to 0.36).
What is the optimal size of the PARITy CAC? Analysis of 
CAC size showed a stable maximum Fleiss kappa of 0.46 
(95% CI 0.50 to 0.35) at CAC sizes of three members or 
more. No significant additional increase in kappa values 
was observed when CAC sizes larger than three members 
were constructed (Fig. 1).
Do formal consensus meetings change the results sig-
nificantly from the majority opinion of independent 
reviewers? In total, 62% of all cases required consensus 
discussion. the average discussion time to reach a con-
sensus was three minutes; this ranged from one minute 
to seven minutes. the consensus of the panel differed 
from the majority individual opinion in 17% of all cases. 
In this minority of cases, the most common conclusion 
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was that the CAC was unable to assess the presence or 
absence of infection or reach an agreement on categori-
sation based on CDC criteria due to inadequate clinical 
information.
Discussion
the complication of surgical site infection after endopros-
thetic reconstruction of the lower limb in orthopaedic 
oncology is a major source of morbidity for this group of 
patients. the PARItY trial is a large multicentre trial inves-
tigating the utility of long-duration antibiotics in decreas-
ing the rate of surgical site infection. In order to investigate 
the outcome of infection in PARItY, and any large surgi-
cal trial, reliably, investigators must be able to agree on 
whether or not a study participant has developed a surgi-
cal site infection. the data in this study provide evidence 
that the use of the current CAC will provide a reasonable 
level of agreement when asked to determine the 
presence or absence of infection. the subclassification of 
level of infection according to the CDC criteria, however, 
is less reliable. these data overall support the current 
PARItY CAC protocol which will require the committee to 
reach a consensus only as to the presence or absence of 
surgical site infection.
the study has a number of limitations. First, there is no 
universal standard for a kappa value that describes 
acceptable or unacceptable levels of agreement.15 
though the agreement can be quantified statistically, 
there is no consensus in the literature as to an acceptable 
cut-off value for level of agreement, and this probably 
varies according to context. second, although the cases 
used in this study were carefully selected to be represent-
ative of the type of cases that will be encountered in the 
PARItY trial, the clinical data were selected retrospectively 
from existing records at multiple cancer centres and may 
not actually be representative. the information recorded 
for the clinical vignettes may have suffered from multiple 
collection and reporting biases inherent in the construc-
tion of a patient's chart. these limitations likely contrib-
uted to the five out of 29 cases where the panelists’ 
consensus position was that they were unable to assess 
the presence or absence of infection due to inadequate 
available clinical information. However, this study dem-
onstrates a minimum level of agreement of the CAC in 
the determination of all possible categorisations, includ-
ing ‘unable to assess’. It is unlikely that the level of agree-
ment would decrease with the provision of additional 
clinical information. It should be noted that the PARItY 
trial will collect data prospectively based on standardised 
reporting requirements. Finally, it should also be noted 
that some of the reviewers expressed that there was a 
learning curve associated with the implementation of the 
CDC criteria regarding the survey cases. As this research 
also served as a training exercise for the PARItY CAC, the 
acclimatisation of the reviewers may have decreased the 
inter- and intra-rater agreement observed in the study. 
Table I. Comparison of inter- and intra-rater agreement of the PARItY Central Adjudication Committees (CAC) in the classification of post-operative infection 
using the Centers for Disease Control (CDC) criteria for surgical site infection and aggregated ‘any infection’ and ‘no infection’ categories with 95% confidence 
intervals
Kappa Significance
Inter-rater reliability Fleiss kappa  
 Infection vs no infection 0.43 (p < 0.001, 0.34 to 0.52) Moderate agreement
  No infection 0.59 (p < 0.001, 0.47 to 0.70) Moderate agreement
  Infection 0.46 (p < 0.001, 0.35 to 0.58) Moderate agreement
  unable to assess 0.07 (p = 0.22, 0.00 to 0.19) slight agreement
 CDC 0.35 (p < 0.001, 0.28 to 0.42) Fair agreement
  No infection 0.59 (p = 0.01, 0.47 to 0.70) Moderate agreement
  superficial incisional infection 0.15 (p < 0.001, 0.03 to 0.26) slight agreement
  Deep incisional infection 0.24 (p < 0.001, 0.12 to 0.35) Fair agreement
  organ/space infection 0.27 (p < 0.001, 0.16 to 0.39) Fair agreement
  unable to assess 0.07 (p = 0.22, 0.00 to 0.19) slight agreement
Intra-rater reliability the Cohen kappa  
 Infection vs no infection 0.68 (0.47 to 0.87) substantial agreement
 CDC 0.57 (0.39 to 0.75) Moderate agreement
0.20
0.30
0.40
0.50
0.60
0.70
1 2 3 4 5 6
Ka
p
p
a
CAC size
Fig. 1
Flow chart showing the comparison of Fleiss kappa agreement of increasing 
central adjudication committees (CAC) size following combinatorial analysis 
of individual respondent’s classifications of surgical site infection. Error bars 
depict 95% confidence intervals of kappa values. A maximum stable kappa 
value can be seen at CAC sizes of greater than three.
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the completion of this study should minimise the impact 
of the learning curve on the final outcomes assessment of 
the PARItY trial.
two previous studies have used the CDC classification 
system for post-operative surgical site infection, how-
ever, the system remains largely invalidated.8 our con-
clusion from this study suggests that using the full 
classification system decreases the level of agreement 
between reviewers to ‘fair’. the decrease in the kappa 
value associated with increasing the level of subclassifica-
tion is consistent with results from other nested classifica-
tion systems in the orthopaedic literature.19-21 When 
these independent assessments were pooled in the final 
consensus meeting, it was noted that critical pieces of 
information, such as cultures or laboratory results that 
would be required for classification under the CDC sys-
tem, were either not recorded or not routinely collected 
in standard patient follow-up. As such, the results of the 
study do not support using the full CDC classification sys-
tem to differentiate between levels of post-operative 
infection when chart data are reviewed retrospectively. It 
is possible that in the context of a prospective study such 
as the PARItY trial, additional information could be rou-
tinely collected to meet the requirements of the CDC 
classification system. However, the clinical importance of 
differentiating between levels of infection remains uncer-
tain. superficial infections may not require re-operation 
for irrigation and debridement, nonetheless there is a 
possibility that these infections may progress to deep 
infections and therefore should be encapsulated in stud-
ies investigating infection as an outcome.
the results of this study suggest that there is a high 
level of agreement between reviewers in determining 
the presence or absence of infection. For outcomes with 
a high degree of agreement, Walter et al4 suggested that 
only three adjudicators are required. larger committees 
increase the expense and logistical difficulty, but often 
do not yield significant statistical benefit. the study to 
Prospectively Evaluate Reamed Intramedullary Nails in 
tibial Fracture (sPRINt) investigators demonstrated that 
reducing their adjudication committee from six to four 
members would not have altered their study findings 
and would have reduced incremental adjudication costs 
by nearly $100 000.3 total time saving would have been 
approximately 18 000 man hours. use of an odd number 
of committee members is considered to be particularly 
important for resolving disagreements and achieving 
consensus.3 Although the methodology used in this 
study differs from that used by Walter et al, a similar con-
clusion was reached. there is no significant benefit to 
inter-reviewer agreement when CAC sizes of greater 
than three are used. on a practical level, a reasonable 
number of additional members may allow for consistent 
full quorum participation as the PARItY study 
progresses.
this study did not demonstrate that formal consensus 
meetings would change the interpretation of the majority 
of cases sent to the CAC for review. Nonetheless, a sub-
stantial minority of case outcomes were changed by the 
consensus meeting. the reviewers involved indicated that 
the interactive discussion of cases subjectively improved 
the reliability of their interpretation by uncovering system-
atic errors in the application of the CDC criteria that would 
otherwise bias results. the meeting also created a univer-
sal standard for interpretation of cases sent to the CAC in 
situations where the CDC criteria could be interpreted dif-
ferently by different reviewers. the ability to reflect on the 
overall protocol and the information required for the 
PARItY CAC was also considered valuable.
the use of CACs is intended to reduce the amount of 
bias that is inherent in large multicentre trials where mul-
tiple investigators may make independent decisions as to 
the study outcome. this study demonstrates that a small 
CAC can use the CDC guidelines for post-operative surgi-
cal site infection to determine the presence or absence of 
infection reliably. there is a substantial decrease in relia-
bility when CAC members are asked to differentiate 
between the categories of the CDC guidelines. Consensus 
meetings are an efficient and effective method of manag-
ing disagreement among CAC members.
Supplementary material
A figure showing an example of a clinical vignette 
and tables showing the sum of reviewer responses 
for each reviewed case and Centers for Disease Control 
criteria for a deep post-operative wound infection can 
be found alongside this paper at http://www.bjr.
boneandjoint.org.uk/
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